Abstract: A power transistor includes a plurality of transistor cells. Each transistor cell has a first electrode coupled to a first electrode interconnection region overlying a first major surface, a control electrode coupled to a control electrode interconnection region overlying the first major surface, and a second electrode coupled to a second electrode interconnection region overlying a second major surface. Each transistor cell has an approximately constant doping concentration in the channel region. A dielectric platform is used as an edge termination of an epitaxial layer to maintain substantially planar equipotential lines therein. The power transistor finds particular utility in radio frequency applications operating at a frequency greater than 500 megahertz and dissipating more than 5 watts of power. The semiconductor die and package are designed so that the power transistor can efficiently operate under such severe conditions.

Abstract: In one embodiment, a semiconductor device is formed in a body of semiconductor material. The semiconductor device includes a localized region of doping near a portion of a channel region where current exits during operation.

Abstract: This invention describes novel pyrazole compounds of formula IV: wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are independently selected from T-R3, or taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 1-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen; and R2, R2?, T, and R3 are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.

Abstract: Disclosed is an assay device comprising liquid transport means adapted to take up a liquid sample and conduct the liquid to an analyte detection region operable to provide a test signal indicative of the presence and/or amount of an analyte in the liquid sample; the assay device further comprising a sample presence signal generation means, which is not generated by means of an immunoreaction. This sample presence signal generation means can comprise a coloured portion, which is overlaid by a material (e.g. nitrocellulose) that is opaque, when dry, and translucent or transparent, when wet, to allow the coloured portion to become visible to the user. In another embodiment the signal generation means comprises a colour changing material which under-goes a change in its visible properties upon wetting (eg. pH indication). A third embodiment uses a mobilisable detectable which, when wetted by the sample, is carried along resulting in a streaked line parallel with the flow direction.

Abstract: This invention describes novel pyrazole compounds of formula IIc: wherein R1 is T-Ring D, wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-7 membered ring having 0-3 heteroatoms; and R2 and R2? are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.

Abstract: An integrated circuit (10) includes a semiconductor substrate (11) that has a top surface (32) for forming a dielectric region (14) with a trench (40) and one or more adjacent cavities (16). A conductive material such as copper is disposed within the trench to produce an inductor (50). A top surface (49) of the inductor is substantially coplanar with an interconnect surface (31) of the semiconductor substrate, which facilitates connecting to the inductor with standard integrated circuit metallization (57).

Abstract: A system for communicating data comprising a client station adapted to connect to a server station by a wireless contention link for exchanging data between the client station and the server station, where the data exchanged has loose quality of service requirements. The client station is also adapted to connect to the server station by at least one wireless non-contenition link for transmitting data from the server station to the client station where the data transmitted has stringent quality of service requirements.

Abstract: Described herein are benzisoxazole compounds of formula I: or a pharmaceutically acceptable derivative or prodrug thereof, wherein A-B is N—O or O—N; Ar is an optionally substituted C5-10 aryl group; R1 is hydrogen or an optionally substituted group selected from C1-10 aliphatic, C5-10 aryl, C6-12 aralkyl, C3-10 heterocyclyl, or C4-12 heterocyclylalkyl; and T, n, R2 and R3 are as described in the specification. These compounds are inhibitors of protein kinases, particularly inhibitors of GSK-3 and JAK mammalian protein kinases. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compounds and compositions in the treatment of various protein kinase mediated disorders.

Abstract: Sampling of program execution may be used to provide sampling data useful in identifying phases of a program.

Abstract: An antenna diversity receiver comprises a zero-IF receiver connected to two antennas (102a, 102b) via switches (532, 534). Simultaneous measurement of signal qualities from both antennas is possible by routing signals from the first antenna (102a) via a first mixer (106) and channel filter (116) and routing signals from the second antenna (102b) via a second mixer (108) and channel filter (118). A diversity controller (536) compares the signal qualities received from the antennas (102a, 102b) during a data preamble to select a preferred antenna, then adjusts the switches (532, 534) to route the signals from the preferred antenna to both input mixers (106, 108). The amplifier (104a, 104b) connected to the deselected antenna may be switched off during data reception, thereby minimising extra power consumption. Such an antenna diversity receiver enables effective antenna selection to be performed, even in systems such as Bluetooth where only a very short preamble is provided for receiver configuration.

Abstract: An aircraft comprises a wing tip device, for example a winglet, a raked-tip device, a wing tip fence or a planar wing extension, mounted in the region of the tip of a wing on the aircraft. The wing tip device is rotatably moveable between a first position and a second position, in which the upward lift produced by the wing or the wing tip device is reduced. During flight, the bending moment at the root of the aircraft wing therefore changes in dependence on the position of the wing tip device. The maximum bending moment in the aircraft wing sustained during high-load conditions is thereby reduced, allowing the structural mass of the aircraft to be reduced.

Abstract: This invention describes novel pyrazole compounds of formula III: wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered carbocyclo ring; and R2 and R2? are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.

Abstract: Described herein are benzisoxazole compounds of formula I: or a pharmaceutically acceptable derivative or prodrug thereof, wherein A-B is N—O or O—N; Ar is an optionally substituted C5-10 aryl group; R1 is hydrogen or an optionally substituted group selected from C1-10 aliphatic, C5-10 aryl, C6-12 aralkyl, C3-10 heterocyclyl, or C4-12 heterocyclylalkyl; and T, n, R2 and R3 are as described in the specification. These compounds are inhibitors of protein kinases, particularly inhibitors of GSK-3 and JAK mammalian protein kinases. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compounds and compositions in the treatment of various protein kinase mediated disorders.

Abstract: The invention relates to mammalian cell lines and transgenic mammals. More particularly, it relates to a method for producing a rat cell line, a method for producing a transgenic rat, a transgenic rat, a rat cell line, cells and tissue obtained therefrom and uses therefore. The cell line derived from a transgenic mammal comprises: (i) a conditional oncogene, transforming gene or immortalising gene or a cell cycle affecting gene; and (ii) a cell type specific promoter. They include a neuronal cell line in which the cell type specific promoter is an NF-L gene promoter, and a mammary cell line in which the cell type specific promoter is a MMTV gene promoter. The conditional oncogene, transforming gene or immortalising gene is preferably a SV40tsA58 gene.

Abstract: This invention describes novel pyrazole compounds of formula IV: 1

Abstract: This invention describes novel pyrazole compounds of formula II: 1

Abstract: This invention describes novel pyrazole compounds of formula II: wherein Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl ring, and R2, R2′, Rx, and Ry are as described in the specification. Ring C has an ortho substituent and is optionally substituted in the non-ortho positions. R2 and R2′ are optionally taken together with their intervening atoms to form a fused ring system, such as an indazole ring; and Rx and Ry are optionally taken together with their intervening atoms to form a fused ring system, such as a quinazoline ring. The compounds are useful as protein kinase inhibitors, especially as inhibitors of GSK-3, for treating diseases such as diabetes and Alzheimer's disease.

Abstract: A reinforcing block for a closure tilt latch, comprising a body fastened in a closure track fastened to a frame, said body having a top and bottom and having a locking detent extending therein said locking detent providing a vertical face extending toward said top of said body from intermediate said top and bottom, the tilt latch being compatible with the vertical face of said locking detent, wherein when said latch engages said detent said block provides a reinforcement path to the closure frame to strengthen the loading capability of said closure and to reduce the risk of the latch from disengaging said track under loading which track would be subject to distortion had the block not been utilized.

Abstract: Described herein are benzisoxazole compounds of formula I: 1

Abstract: This invention describes novel pyrazole compounds of formula IV: wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx and Ry are independently selected from T-R3, or taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 1-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen; and R2, R2, T, and R3 are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.